Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEM-288 Oncolytic Virus in Advanced Solid Tumors
NCT05076760Phase 1Recruiting
- Sponsor
- Memgen
- Start
- Apr 2022
- Primary completion
- Feb 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of MEM-288 in solid tumor, non-small cell lung cancer (NSCLC), cutaneous squamous cell carcinoma (cSCC) and 5 more (3 arms), sponsored by Memgen. Primary endpoints: Maximum Tolerated Dose at 21 days and Adverse Events at 4.5 months. Started Apr 2022; status: recruiting.
02
Drugs
MEM-288
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)cutaneous squamous cell carcinoma (cSCC)Merkel cell carcinoma (MCC)melanoma
Beyond the preview
Go deeper on NCT05076760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05076760.